Biotech Stocks Drop Sharply After Disappointing Bone Disease Drug Trials
TL;DR Summary
Shares of Ultragenyx and Mereo BioPharma plummeted after their Phase 3 trial for the brittle-bone disease treatment setrusumab failed to meet primary endpoints, despite secondary improvements in bone density, leading to significant market value losses and cautious outlooks from analysts.
- These biotech stocks are getting hammered by shocking brittle-bone treatment study results MarketWatch
- Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate Reuters
- Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta Yahoo Finance
- Brittle bone drug trial falls short on fractures as firm cuts costs Stock Titan
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials TipRanks
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
92%
514 → 40 words
Want the full story? Read the original article
Read on MarketWatch